-
公开(公告)号：KR101901741B1
公开(公告)日：2018-10-01
申请号：KR1020110090896
申请日：2011-09-07
Applicant: 서울대학교산학협력단
IPC: C07D493/10 , A61K31/352 , A61P3/10 , A61P9/00
CPC classification number: C07D493/10 , A61K31/352 , A61K31/4184 , A61K31/4192 , A61K31/422 , A61K31/453 , A61K31/496 , A61K31/541 , A61K31/665 , A61K31/7048 , A61K45/06 , C07D493/20 , C07F9/65615 , C07H17/04
Abstract: 본발명은세스터터핀화합물, 생체내에서가수분해가능한그의전구체또는약제학적으로허용가능한그의염 및세스터터핀화합물이갖는인슐린비의존성당뇨병, 당뇨합병증(당뇨병에의한신부전증및 족부궤양증), 알콜성, 비알콜성및 바이러스성지방간질환, 비만, 고지혈증, 동맥경화증(atherosclerosis), 동맥경화성중품과같은심혈관계질환, 뇌질환(파킨슨병, 조울증, 정신분열증및 알츠하이머병)에대한예방및 치료효능에관한것이다. 또한본 발명은이들물질의기능성식품, 기능성음료, 기능성화장품및 기능성사료의조성물제공에관한것이다. 본발명의세스터터핀화합물은당뇨병과더불어지방간, 비만외에도고지혈증, 동맥경화증과같은심혈관계질환예방및 치료에우수한효능이있다. 또한저밀도콜레스테롤(LDL) 감소와대식세포유래염증사이토카인및 간에서의지방생합성효소의발현억제를통하여기존핵수용체 LXR 활성물질(agonists)와복합제제로고지혈증, 동맥경화와심혈관계질환을예방및 치료할수 있다. 더욱이신경세포의도파민항상성에관여하는단백질을활성화하여단일제제로파킨슨병, 조울증및 정신분열증을예방치료제로사용할수 있다. 또한본 발명의화합물은기존 LXR 활성물질의부작용인지방간을억제함으로써, 알츠하이머병예방및 치료효능이알려져있는문헌에보고된핵수용체 LXR 활성물질(agonists)와복합제제로알츠하이머병예방및 치료제로서사용될수 있다. 또한, Nurr1 활성물질로써알츠하이머와더불어파킨슨병및 치매(dementia)과같은뇌질환예방및 치료제로이용가능하다.
-
公开(公告)号：KR1020140082451A
公开(公告)日：2014-07-02
申请号：KR1020120152442
申请日：2012-12-24
Applicant: 서울대학교산학협력단
IPC: A61K31/426 , A61K31/435 , A61P17/02 , A61P17/00
CPC classification number: A61K31/426 , A61K31/192 , A61K31/41 , A61K31/42 , A61K31/427 , A61K31/4439 , Y10S424/13 , Y10S514/925
Abstract: The present invention relates to a novel use of a PPARδ agonist and, particularly, to antibacterial activities, diabetic foot ulcer treatment and prevention ettects, and gash and burn treatment effects of a PPARδ agonist. According to the present invention, the PPARδ agonist has excellent antibacterial activities against methicillin- and vancomycin-resistant bacteria and can be used as an agent for preventing or treating multidrug resistance bacterial infection. The PPARδ agonist has excellent wound treating efficiency through the cell movement and proliferation of epidermal keratinocytes and has excellent ulcer treating efficiency in a diabetic ulcer animal model, so as to effectively treat gash, burn, and foot ulcer caused by diabetic complications.
Abstract translation: 本发明涉及PPARδ激动剂的新用途，特别涉及抗菌活性，糖尿病足溃疡治疗和预防疗法，以及PPARδ激动剂的间隙和烧伤治疗效果。 根据本发明，PPARδ激动剂对抗甲氧西林和万古霉素抗性细菌具有优异的抗菌活性，可用作预防或治疗多药耐药细菌感染的药剂。 PPARδ激动剂通过细胞运动和表皮角化细胞增殖具有优异的伤口治疗效果，并且在糖尿病溃疡动物模型中具有优异的溃疡治疗效果，从而有效治疗由糖尿病并发症引起的沟槽，烧伤和足部溃疡。
-
公开(公告)号：KR102038866B1
公开(公告)日：2019-10-31
申请号：KR1020120152442
申请日：2012-12-24
Applicant: 서울대학교산학협력단
IPC: A61K31/426 , A61K31/427 , A61K31/41 , A61K31/192 , A61K31/4439
-
公开(公告)号：KR1020120025440A
公开(公告)日：2012-03-15
申请号：KR1020110090896
申请日：2011-09-07
Applicant: 서울대학교산학협력단
IPC: C07D493/10 , A61K31/352 , A61P3/10 , A61P9/00
CPC classification number: C07D493/10 , A61K31/352 , A61K31/4184 , A61K31/4192 , A61K31/422 , A61K31/453 , A61K31/496 , A61K31/541 , A61K31/665 , A61K31/7048 , A61K45/06 , C07D493/20 , C07F9/65615 , C07H17/04
Abstract: PURPOSE: A sesterterpen compound and a composition containing the same are provided to prevent and treat diabetes, fatty liver, and obesity. CONSTITUTION: A sesterterpen compound is denoted by chemical formula I. A pharmaceutical composition for preventing and treating diabetes, diabetes complication, cardiovascular diseases or obesity contains sesterterpen compounds, stereoisomer, enantiomer, hybridizable precursor, or pharmaceutically acceptable salt thereof. A pharmaceutical composition for preventing and treating cardiovascular diseases contains sesterterpen compounds of chemical formula I, stereoisomer, enantiomer, in vivo hybridizable precursor thereof, or pharmaceutically acceptable salt thereof, and LXR agonist.
Abstract translation: 目的：提供西酯化合物和含有它们的组合物以预防和治疗糖尿病，脂肪肝和肥胖。 构成：化学式I表示酯化合物。用于预防和治疗糖尿病，糖尿病并发症，心血管疾病或肥胖症的药物组合物含有酯化合物，立体异构体，对映异构体，可杂交前体或其药学上可接受的盐。 用于预防和治疗心血管疾病的药物组合物含有化学式I的酯化合物，立体异构体，对映异构体，体内可杂交的前体或其药学上可接受的盐和LXR激动剂。
-
-
-
Search Results
4
records
(took 0.019 seconds)
